# A Study to Determine the Safety and Sensitizing Potential of HAT1 Topical Products Using Skin Sensitivity Patch Tests

> **NCT03406117** · PHASE4 · COMPLETED · sponsor: **Haus Bioceuticals** · enrollment: 182 (actual)

## Conditions studied

- Healthy
- Atopic Dermatitis
- Psoriasis

## Interventions

- **DRUG:** HAT1
- **OTHER:** Saline Solution

## Key facts

- **NCT ID:** NCT03406117
- **Lead sponsor:** Haus Bioceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-01
- **Primary completion:** 2016-06-26
- **Final completion:** 2016-07-21
- **Target enrollment:** 182 (ACTUAL)
- **Last updated:** 2018-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03406117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03406117, "A Study to Determine the Safety and Sensitizing Potential of HAT1 Topical Products Using Skin Sensitivity Patch Tests". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03406117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*